Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

12.73 -0.43 (-3.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,390,288
Open 13.08
Bid (Size) 12.61 (100)
Ask (Size) 12.80 (300)
Prev. Close 13.16
Today's Range 12.22 - 13.21
52wk Range 12.07 - 30.05
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger Opportunity ↗
Could these 2 stocks outperform most GLP-1-focused companies over the medium term? 
Via The Motley Fool
News headline image
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
From Summit Therapeutics
Via Business Wire

Performance

YTD
-27.3%
-27.3%
1 Month
-6.8%
-6.8%
3 Month
-25.1%
-25.1%
6 Month
-20.9%
-20.9%
1 Year
-51.5%
-51.5%

More News

Read More
News headline image
Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
From Summit Therapeutics
Via Business Wire
Summit Therapeutics (SMMT) Reports In-Line Q2 Loss; Stock Eases Amid Pivotal PDUFA Catalyst ↗
Via Chartmill
News headline image
Summit Therapeutics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
From Summit Therapeutics
Via Business Wire
News headline image
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
From Summit Therapeutics
Via Business Wire
News headline image
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Summit Therapeutics Announces Proposed Public Offering of Common Stock
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
From Summit Therapeutics
Via Business Wire
News headline image
This Emerging Risk Is Unlike Anything the Biotech Industry Has Ever Experienced ↗
Via The Motley Fool
News headline image
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
From Summit Therapeutics
Via Business Wire
News headline image
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
From Summit Therapeutics
Via Business Wire
News headline image
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
Via The Motley Fool
News headline image
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
From USA News Group
Via GlobeNewswire
What's going on in today's session ↗
Via Chartmill
Which stocks are moving on Friday? ↗
Via Chartmill
News headline image
Summit Therapeutics Stock Dips After Q1 Financial Report ↗
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill

Frequently Asked Questions

Is Summit Therapeutics Inc. - Common Stock publicly traded?
Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Summit Therapeutics Inc. - Common Stock trade on?
Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?
The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market
What is the current price of Summit Therapeutics Inc. - Common Stock?
The current price of Summit Therapeutics Inc. - Common Stock is 12.73
When was Summit Therapeutics Inc. - Common Stock last traded?
The last trade of Summit Therapeutics Inc. - Common Stock was at 08/24/26 04:00 PM ET
What is the market capitalization of Summit Therapeutics Inc. - Common Stock?
The market capitalization of Summit Therapeutics Inc. - Common Stock is 1.24B
How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?
Summit Therapeutics Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.